TW202132269A - 登革熱疾病及治療和預防 - Google Patents
登革熱疾病及治療和預防 Download PDFInfo
- Publication number
- TW202132269A TW202132269A TW109139793A TW109139793A TW202132269A TW 202132269 A TW202132269 A TW 202132269A TW 109139793 A TW109139793 A TW 109139793A TW 109139793 A TW109139793 A TW 109139793A TW 202132269 A TW202132269 A TW 202132269A
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- log
- copies
- series
- dengue
- Prior art date
Links
- 208000025729 dengue disease Diseases 0.000 title claims abstract description 70
- 238000011282 treatment Methods 0.000 title abstract description 57
- 230000002265 prevention Effects 0.000 title abstract description 12
- 206010012310 Dengue fever Diseases 0.000 claims abstract description 61
- 239000003814 drug Substances 0.000 claims abstract description 56
- 208000001490 Dengue Diseases 0.000 claims abstract description 55
- 241000725619 Dengue virus Species 0.000 claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 202
- 230000003612 virological effect Effects 0.000 claims description 69
- 229940079593 drug Drugs 0.000 claims description 43
- 210000004369 blood Anatomy 0.000 claims description 37
- 239000008280 blood Substances 0.000 claims description 37
- 230000037396 body weight Effects 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 241000700605 Viruses Species 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 239000012453 solvate Substances 0.000 claims description 9
- 150000002475 indoles Chemical class 0.000 abstract description 7
- 150000002476 indolines Chemical class 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 69
- 208000015181 infectious disease Diseases 0.000 description 51
- 239000003981 vehicle Substances 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 27
- 206010058874 Viraemia Diseases 0.000 description 27
- 108020000999 Viral RNA Proteins 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 23
- 238000001727 in vivo Methods 0.000 description 20
- 230000002354 daily effect Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 241000282560 Macaca mulatta Species 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 10
- 239000000460 chlorine Substances 0.000 description 10
- 239000001257 hydrogen Substances 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 238000011321 prophylaxis Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 230000003449 preventive effect Effects 0.000 description 8
- 238000011269 treatment regimen Methods 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 7
- 230000002064 post-exposure prophylaxis Effects 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002054 inoculum Substances 0.000 description 6
- 208000009714 Severe Dengue Diseases 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000003111 delayed effect Effects 0.000 description 4
- 150000002431 hydrogen Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- 241000256111 Aedes <genus> Species 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 241000256173 Aedes albopictus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000282553 Macaca Species 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- -1 elixirs Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- NKRAIOQPSBRMOV-NRMKKVEVSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-3-ethynyl-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)C#C NKRAIOQPSBRMOV-NRMKKVEVSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- PPUDLEUZKVJXSZ-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 PPUDLEUZKVJXSZ-VPCXQMTMSA-N 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 241000256118 Aedes aegypti Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001522306 Serinus serinus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- HTJGLYIJVSDQAE-VWNXEWBOSA-N [(1s,6s,7s,8r,8ar)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate Chemical compound O[C@H]1[C@H](O)[C@@H](OC(=O)CCC)CN2CC[C@H](O)[C@@H]21 HTJGLYIJVSDQAE-VWNXEWBOSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229950003414 celgosivir Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 201000002950 dengue hemorrhagic fever Diseases 0.000 description 1
- 201000009892 dengue shock syndrome Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19209593 | 2019-11-15 | ||
| EP19209593.3 | 2019-11-15 | ||
| EP19213851.9 | 2019-12-05 | ||
| EP19213851 | 2019-12-05 | ||
| EP20171172 | 2020-04-23 | ||
| EP20171172.8 | 2020-04-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202132269A true TW202132269A (zh) | 2021-09-01 |
Family
ID=73288639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109139793A TW202132269A (zh) | 2019-11-15 | 2020-11-13 | 登革熱疾病及治療和預防 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220409583A1 (https=) |
| EP (1) | EP4058019A1 (https=) |
| JP (1) | JP2023502053A (https=) |
| KR (1) | KR20220101679A (https=) |
| CN (1) | CN114980884A (https=) |
| AU (1) | AU2020382911A1 (https=) |
| BR (1) | BR112022009199A2 (https=) |
| CA (1) | CA3161338A1 (https=) |
| IL (1) | IL292970A (https=) |
| MX (1) | MX2022005879A (https=) |
| PH (1) | PH12022551160A1 (https=) |
| TW (1) | TW202132269A (https=) |
| UA (1) | UA129409C2 (https=) |
| WO (1) | WO2021094563A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023218285A1 (en) * | 2022-05-12 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Treatment or prevention of dengue viral infection |
| WO2025248536A1 (en) * | 2024-05-29 | 2025-12-04 | Zydus Lifesciences Limited | Novel oxime derivatives to treat viral infections |
| WO2025253267A1 (en) | 2024-06-06 | 2025-12-11 | Janssen Pharmaceuticals, Inc. | Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
-
2020
- 2020-11-13 CA CA3161338A patent/CA3161338A1/en active Pending
- 2020-11-13 WO PCT/EP2020/082102 patent/WO2021094563A1/en not_active Ceased
- 2020-11-13 AU AU2020382911A patent/AU2020382911A1/en active Pending
- 2020-11-13 MX MX2022005879A patent/MX2022005879A/es unknown
- 2020-11-13 EP EP20803432.2A patent/EP4058019A1/en active Pending
- 2020-11-13 UA UAA202202003A patent/UA129409C2/uk unknown
- 2020-11-13 PH PH1/2022/551160A patent/PH12022551160A1/en unknown
- 2020-11-13 JP JP2022528008A patent/JP2023502053A/ja active Pending
- 2020-11-13 US US17/777,019 patent/US20220409583A1/en active Pending
- 2020-11-13 IL IL292970A patent/IL292970A/en unknown
- 2020-11-13 TW TW109139793A patent/TW202132269A/zh unknown
- 2020-11-13 BR BR112022009199A patent/BR112022009199A2/pt unknown
- 2020-11-13 CN CN202080093897.0A patent/CN114980884A/zh active Pending
- 2020-11-13 KR KR1020227020173A patent/KR20220101679A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220101679A (ko) | 2022-07-19 |
| UA129409C2 (uk) | 2025-04-16 |
| CA3161338A1 (en) | 2021-05-20 |
| EP4058019A1 (en) | 2022-09-21 |
| JP2023502053A (ja) | 2023-01-20 |
| US20220409583A1 (en) | 2022-12-29 |
| CN114980884A (zh) | 2022-08-30 |
| PH12022551160A1 (en) | 2023-09-25 |
| WO2021094563A1 (en) | 2021-05-20 |
| MX2022005879A (es) | 2022-06-14 |
| AU2020382911A1 (en) | 2022-06-30 |
| IL292970A (en) | 2022-07-01 |
| BR112022009199A2 (pt) | 2022-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240269125A1 (en) | Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent | |
| TW202132269A (zh) | 登革熱疾病及治療和預防 | |
| CN105636589B (zh) | 脱氧野尻霉素衍生物及其使用方法 | |
| EP4129290B1 (en) | Pharmaceutical composition comprising pyronaridine or a salt thereof, artemisinin or a derivative thereof or a combination of both for preventing or treating a respiratory disease caused by a coronavirus | |
| CN109789147B (zh) | 用于治疗非酒精性脂肪性肝病的药物组合物及方法 | |
| JP2001072585A (ja) | ウイルス性心筋炎の予防または治療薬剤 | |
| CN116940360B (zh) | 5-硝基-8-羟基喹啉的应用 | |
| Seiberling et al. | Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist | |
| EA049504B1 (ru) | Лечение и профилактика лихорадки денге | |
| CN102335171B (zh) | 一类n-(2-噻唑)苯甲酰胺衍生物的应用 | |
| HK40074715A (en) | Treatment and prevention of dengue disease | |
| WO2023070058A1 (en) | Treatment of viruses with antiviral nucleosides | |
| CN113440527B (zh) | 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用 | |
| JP7046015B2 (ja) | ジカウイルス感染の治療のための方法及び組成物 | |
| JP2024533532A (ja) | コロナウイルス感染症を処置するための新規の併用薬物、医薬組成物およびその使用 | |
| EP3960173B1 (en) | Enterovirus inhibitor | |
| CN106727574A (zh) | 马尼地平在制备治疗黄病毒科病毒感染药物中的应用 | |
| Yang et al. | Norovirus: Clinical Findings and Pharmaceutical Developments | |
| CN121466087A (zh) | Pha-767491在制备防治h1n1亚型猪流感药物中的应用 | |
| KR20250002212A (ko) | 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법 | |
| CN121445739A (zh) | Pha-767491作为h3n2亚型猪流感病毒复制抑制剂的应用 | |
| HK40107522A (en) | New combination drug for treating coronavirus infections, pharmaceutical composition and use thereof | |
| JP2007210987A (ja) | ウイルス性疾患の予防または治療剤 |